Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial
Introduction Subarachnoid haemorrhage (SAH) from a ruptured cerebral aneurysm carries high morbidity and mortality. Despite huge advances in techniques to secure the aneurysm, there has been little progress in the treatment of the deleterious effects of the haemorrhage.Sulforaphane is an Nrf2 induce...
Saved in:
| Main Authors: | Ardalan H Zolnourian, Stephen Franklin, Diederik Oliver Bulters |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/3/e028514.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
C-reactive protein and fatigue after subarachnoid haemorrhage
by: Sean Daniel, et al.
Published: (2025-10-01) -
Seizure prophylaxis following aneurysmal subarachnoid haemorrhage (SPSAH): study protocol for a multicentre randomised placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute subarachnoid haemorrhage
by: Qiaowei Wu, et al.
Published: (2022-05-01) -
SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2
by: Hyun-Ju Cho, et al.
Published: (2025-07-01) -
Remote ischaemic conditioning for efficacy in patients with aneurysmal subarachnoid haemorrhage (REPAIR): protocol for a multicentre, randomised, double-blind, sham-controlled, parallel-group trial
by: Yunjian Yin, et al.
Published: (2025-08-01) -
Treatment of acute intracerebral haemorrhage with a Chinese herbal formula (Shengdi Dahuang Decoction): a multicentre, double-blind, randomised, placebo-controlled trial
by: Feng Wang, et al.